AxoGen, Inc. to Report First Quarter Financial Results on April 30, 2014

AxoGen, Inc. will report results for the first quarter ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

AxoGen Logo

Alachua, Florida (PRWEB) April 16, 2014

AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, will report results for the first quarter ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes.

The Company will host a conference call and webcast for the investment community on Wednesday, April 30, 2014 at 4:30 PM ET. To join the call, Investors within the United States are invited to call 1.877.674.2413 and reference the Participant Passcode 28930259. All other participants can use the dial-in number 1.914.495.8604, using the same Participant Passcode. To access the webcast, please visit http://ir.axogeninc.com/. Following the conference call, a replay will be available on the Company’s website at http://www.AxoGenInc.com, under ‘Investors.’

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Source: AxoGen, Inc.


Contact

  • Michael Polyviou
    EVC Group
    212.850.6020
    Email